These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27870945)

  • 1. Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromes.
    Deshet-Unger N; Oster HS; Prutchi-Sagiv S; Maaravi N; Golishevski N; Neumann D; Mittelman M
    Leuk Res; 2017 Jan; 52():20-27. PubMed ID: 27870945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes.
    Voulgari PV; Hatzimichael EC; Tsiara S; Tzallas C; Drosos AA; Bourantas KL
    Eur J Haematol; 2001 Jan; 66(1):31-6. PubMed ID: 11168505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of regulatory T cells in patients with myelodysplastic syndrome.
    Hamdi W; Ogawara H; Handa H; Tsukamoto N; Nojima Y; Murakami H
    Eur J Haematol; 2009 Mar; 82(3):201-7. PubMed ID: 19018862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell function, T-cell phenotype and its role in responsiveness to recombinant human erythropoietin in hemodialysis patients.
    Abdalla M; Yassein S; Darwish KH
    Egypt J Immunol; 2010; 17(2):67-80. PubMed ID: 23082488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expressions of costimulatory molecules on CD3(+)CD4(+) T cells in myelodysplastic syndrome].
    Zeng H; Wu DP; Ouyang J; He GS; Wnag XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1082-5. PubMed ID: 18928600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Changes and clinical significance of CD8(+) T cell subset in patients with aplastic anemia, myelodysplastic syndrome and acute myeloid leukemia].
    Zhang JY; Xu HZ; Yin DM; Feng XM; Sui XH; Cui B; Ma CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):203-8. PubMed ID: 23484720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term therapy with recombinant human erythropoietin increases CD8+ T-cell apoptosis in haemodialysis patients.
    Trzonkowski P; Debska-Slizien A; Szmit E; Myśliwska J; Szymańska K; Hak Ł; Myśliwski A; Rutkowski B
    Nephrol Dial Transplant; 2005 Feb; 20(2):367-76. PubMed ID: 15585513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset.
    Fozza C; Contini S; Galleu A; Simula MP; Virdis P; Bonfigli S; Longinotti M
    Exp Hematol; 2009 Aug; 37(8):947-55. PubMed ID: 19409953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
    Fozza C; Corda G; Barraqueddu F; Virdis P; Contini S; Galleu A; Isoni A; Dore F; Angelucci E; Longinotti M
    Leuk Res; 2015 Sep; 39(9):957-63. PubMed ID: 26209197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the subsets of lymphocytes and their activated status in patients with myelodysplastic syndrome].
    Yang J; Wang C; Xie KC; Yan SK; Gao YR; Cai Q; Qin YW; Wan LP; Cai Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):708-13. PubMed ID: 16928305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome.
    Goy A; Belanger C; Casadevall N; Picard F; Guesnu M; Jaulmes D; Poisson D; Varet B
    Br J Haematol; 1993 Jun; 84(2):232-7. PubMed ID: 8398823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes.
    Runde V; Aul C; Ebert A; Grabenhorst U; Schneider W
    Eur J Haematol; 1995 Jan; 54(1):39-45. PubMed ID: 7859874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome.
    Iwase O; Aizawa S; Kuriyama Y; Yaguchi M; Nakano M; Toyama K
    Ann Hematol; 1995 Dec; 71(6):293-9. PubMed ID: 8534761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes.
    Merchav S; Nielsen OJ; Rosenbaum H; Sharon R; Brenner B; Tatarsky I; Scigalla P; Wieczorek L
    Leukemia; 1990 Nov; 4(11):771-4. PubMed ID: 2232891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes.
    Alfinito F; Sica M; Luciano L; Della Pepa R; Palladino C; Ferrara I; Giani U; Ruggiero G; Terrazzano G
    Br J Haematol; 2010 Jan; 148(1):90-8. PubMed ID: 19793254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?
    Prutchi-Sagiv S; Golishevsky N; Oster HS; Katz O; Cohen A; Naparstek E; Neumann D; Mittelman M
    Br J Haematol; 2006 Dec; 135(5):660-72. PubMed ID: 17107348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of recombinant human G-CSF combined with EPO in treatment of patients with MDS].
    Li ZY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):512-3. PubMed ID: 15972155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients.
    Follo MY; Mongiorgi S; Clissa C; Paolini S; Martinelli G; Martelli AM; Fioravanti G; Manzoli L; Finelli C; Cocco L
    Leukemia; 2012 Dec; 26(12):2474-82. PubMed ID: 22596089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.